DE69023416D1 - Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung. - Google Patents

Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung.

Info

Publication number
DE69023416D1
DE69023416D1 DE69023416T DE69023416T DE69023416D1 DE 69023416 D1 DE69023416 D1 DE 69023416D1 DE 69023416 T DE69023416 T DE 69023416T DE 69023416 T DE69023416 T DE 69023416T DE 69023416 D1 DE69023416 D1 DE 69023416D1
Authority
DE
Germany
Prior art keywords
plate manufacturing
medicinal products
increase plate
increase
medicinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69023416T
Other languages
English (en)
Other versions
DE69023416T2 (de
Inventor
Douglas Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of DE69023416D1 publication Critical patent/DE69023416D1/de
Application granted granted Critical
Publication of DE69023416T2 publication Critical patent/DE69023416T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69023416T 1989-02-17 1990-02-06 Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung. Expired - Lifetime DE69023416T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/312,546 US5032396A (en) 1989-02-17 1989-02-17 IL-7 to stimulate platelet production
PCT/US1990/000679 WO1990009194A1 (en) 1989-02-17 1990-02-06 Use of il-7 in providing medications for stimulation of platelet production

Publications (2)

Publication Number Publication Date
DE69023416D1 true DE69023416D1 (de) 1995-12-14
DE69023416T2 DE69023416T2 (de) 1996-06-27

Family

ID=23211955

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69023416T Expired - Lifetime DE69023416T2 (de) 1989-02-17 1990-02-06 Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung.

Country Status (10)

Country Link
US (1) US5032396A (de)
EP (1) EP0412149B1 (de)
JP (1) JP2840443B2 (de)
AT (1) ATE129899T1 (de)
AU (1) AU628943B2 (de)
CA (1) CA2026783C (de)
DE (1) DE69023416T2 (de)
DK (1) DK0412149T3 (de)
ES (1) ES2081366T3 (de)
WO (1) WO1990009194A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714585A (en) * 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US5260417A (en) * 1989-04-03 1993-11-09 Genetics Institute, Inc. Megakaryocyte growth promoting activity protein
US5229115A (en) * 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
WO1992004455A1 (en) * 1990-08-29 1992-03-19 Genetics Institute, Inc. Multidomain hematopoiesis stimulators
US5474769A (en) * 1991-03-08 1995-12-12 Sterling Winthrop Inc. Treatment of microbial infection by monocyte stimulation with interleukin-7
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
AU4190893A (en) * 1992-07-17 1994-01-20 Suntory Limited Megakaryocyte differentiation factor
DE69333782T2 (de) * 1992-12-16 2006-01-26 Hexima Ltd., Melbourne Ein proteinase-inhibitor, vorläufer davon und dafür kodierende genetische sequenzen
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
US5547931A (en) * 1994-02-23 1996-08-20 Immtech International Inc. Methods of stimulatory thrombocytopoiesis using modified C-reactive protein
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
TW565568B (en) * 1994-03-31 2003-12-11 Amgen Inc Compositions and methods for stimulating megakaryocyte growth and differentiation
WO1996016987A1 (fr) * 1994-11-30 1996-06-06 Chugai Seiyaku Kabushiki Kaisha Facteur thrombocytotique
EP0721780A3 (de) * 1994-12-16 1997-12-17 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Mittel zur Förderung von Plättchen und/oder Leucozytenherstellung
FR2745185B1 (fr) * 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
WO2000057891A1 (en) 1999-03-30 2000-10-05 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
EP1324779B1 (de) 2000-09-29 2011-07-20 Schering Corporation Pegyliertes interleukin 10
AU2002307497A1 (en) * 2001-04-23 2002-11-05 The Regents Of The University Of California Methods of using interleukin-7 to modulate physiological processes in mammalian pulmonary fibroblasts
DE602004022427D1 (de) * 2003-09-10 2009-09-17 Cell Biosciences Inc S Zusammensetzungen basierend auf T-4 Immunstimulierender-Faktor ("TISF") zur Behandlung von Mangel and roten Blutkörperchen, Granulocyten un Blutplättchen
CA2664304C (en) 2006-09-28 2017-08-22 Schering Corporation Use of pegylated il-10 to treat cancer
EP2986306A4 (de) 2013-04-18 2016-12-07 Armo Biosciences Inc Verfahren zur verwendung von interleukin-10 zur behandlung von erkrankungen und leiden
US9823255B2 (en) 2013-06-17 2017-11-21 Armo Biosciences, Inc. Method for assessing protein identity and stability
ES2862139T3 (es) 2013-11-11 2021-10-07 Armo Biosciences Inc Procedimientos de uso de Interleucina 10 para el tratamiento de enfermedades y trastornos
WO2015187295A2 (en) 2014-06-02 2015-12-10 Armo Biosciences, Inc. Methods of lowering serum cholesterol
KR20170084033A (ko) 2014-10-22 2017-07-19 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위해 인터루킨-10을 사용하는 방법
WO2016126615A1 (en) 2015-02-03 2016-08-11 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
AU2016312510A1 (en) 2015-08-25 2018-03-08 Armo Biosciences, Inc. Methods of using Interleukin-10 for treating diseases and disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894440A (en) * 1986-09-17 1990-01-16 Massachusetts Institute Of Technology Method of isolating megakaryocyte stimulatory factor
ZA887773B (en) * 1987-10-26 1989-07-26 Immunex Corp Interleukin-7

Also Published As

Publication number Publication date
AU5164590A (en) 1990-09-05
EP0412149A4 (en) 1992-12-09
AU628943B2 (en) 1992-09-24
EP0412149B1 (de) 1995-11-08
US5032396A (en) 1991-07-16
JP2840443B2 (ja) 1998-12-24
EP0412149A1 (de) 1991-02-13
DK0412149T3 (da) 1995-12-11
ATE129899T1 (de) 1995-11-15
ES2081366T3 (es) 1996-03-01
WO1990009194A1 (en) 1990-08-23
JPH04501421A (ja) 1992-03-12
CA2026783C (en) 1996-08-06
DE69023416T2 (de) 1996-06-27
CA2026783A1 (en) 1990-08-18

Similar Documents

Publication Publication Date Title
DE69023416T2 (de) Verwendung von il-7 bei arzneimitteln zur steigerung der plättchenherstellung.
DE3884372D1 (de) Die Verwendung von Maltitiol in Kaugummimassen zur Verbesserung der physikalischen Stabilität.
DE3855423T2 (de) Verfahren zur Herstellung von anatomisch vorgeformten Knochenplatten
DE3381877D1 (de) Verwendung von opium antagonisten zur herstellung von arzneimitteln zur behebung gastro-intestinaler stoerungen.
DE3675169D1 (de) Herstellung von tabletten.
MX165197B (es) Proceso para la produccion de esteres ciclicos
DE69022595D1 (de) Herstellung von kohlefaser-halbfabrikaten.
DE3787197D1 (de) Gerät zur Herstellung von Schichtpressstoffen.
ES549156A0 (es) Procedimiento para la produccion de laminados decorativos
DE3886800D1 (de) Verfahren zur Herstellung von Kautschuklaminaten.
IT1231549B (it) Procedimento per la produzione di semilavorati di cuoio
DE3854799D1 (de) Verfahren zur Herstellung von veränderten Zeolithen
DK0506836T3 (da) BCRF1 proteiner som inhibitorer for interferon-gamma
DE3781054D1 (de) Die verwendung von d-fenfluramin zur herstellung von arzneimitteln, zur behandlung von depressionen.
DE3876769D1 (de) Mikrobiologische herstellung von 9-alpha-hydroxy-17-keto-steroiden.
DE69023989T2 (de) Verwendung von Vitamin B6 zur Verminderung von hohem Serotoninspiegel.
NO864514D0 (no) Fremgangsmaate for fremstilling av thiazoloner.
IT8348214A0 (it) Procedimento per la produzione dipannelli truciolati
IT8921894A0 (it) Procedimento per la produzione di impiallacciatura di radica artificiale mediante fogli di legno rigati.
PT87564A (pt) Process for preparing substituted vinylcephalosporins useful as medicaments
ATE59780T1 (de) Pharmazeutische zusammensetzung zur behandlung von tumoren.
DE3851903T2 (de) Herstellung von Tabletten.
IT1213100B (it) La produzione di prodotti sessuali impiego di sostanze stimolanti per da mammiferi,adatti per la fecondazione naturale ed artificiale e sostanze relative
ATE135910T1 (de) Verwendung von (1r,2r)-n-methyl-2-(3-pyridyl)-2- tetrahydrothiopyrancarbothioamid-1-oxid zur herstellung von arzneimitteln zur behandlung von koronarschwäche
PT86666A (pt) Process for the preparation of pilocarpine by products

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: STERLING WINTHROP INC., NEW YORK, N.Y., US

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI, PARIS, FR

8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-SYNTHELABO, PARIS, FR

8328 Change in the person/name/address of the agent

Free format text: MUELLER, SCHUPFNER & GAUGER, 80539 MUENCHEN